Literature DB >> 11158519

Standard treatment of alpha-tocopherol in Alagille patients with severe cholestasis is insufficient.

A Davit-Spraul1, C Cosson, M Couturier, M Hadchouel, A Legrand, F Lemonnier, P Therond.   

Abstract

Alpha-tocopherol (alpha-T) is the most effective lipid-soluble antioxidant present in cells. We investigated the efficacy of alpha-T supplements for preventing lipid peroxidation in patients with Alagille syndrome, according to the severity of cholestasis. Patients were assigned to two groups on the basis of plasma bilirubin concentration (group I, bilirubin <100 microM; group II, bilirubin >100 microM). alpha-T concentrations were determined in plasma, in isolated lipoproteins, and in red blood cell membranes. In both groups of patients, alpha-T concentrations in plasma were similar to those in control subjects, but the distribution of alpha-T in lipoproteins was affected by the abnormal lipoprotein pattern in these patients. The efficacy of alpha-T was estimated by determining the amount of hydroperoxide produced from phosphatidylcholine and phosphatidylethanolamine (PE) molecular species owing to oxidative stress induced by lipoxygenase treatment. The concentrations of phosphatidylcholine molecular species and its corresponding hydroperoxides were significantly higher in both groups of patients. In group I, alpha-T and PE molecular species concentrations were similar to those in control subjects, but PE hydroperoxide concentrations were higher than those in the control subjects. In group II, alpha-T concentration was significantly lower and the concentrations of some PE molecular species and all PE hydroperoxides were lower than those in the control subjects. In conclusion, erythrocyte membrane alpha-T concentration was significantly lower only in patients with severe jaundice, despite alpha-T supplementation, raising the question as to whether the usual treatment was appropriate in this group.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158519     DOI: 10.1203/00006450-200102000-00017

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  Treatment of Pediatric Cholestatic Liver Disease.

Authors:  Valeria C. Cohran; James E. Heubi
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10

2.  Association of lipid peroxidation with hepatocellular injury in preterm infants.

Authors:  Barry Weinberger; Kazimierz Watorek; Richard Strauss; Gisela Witz; Mark Hiatt; Thomas Hegyi
Journal:  Crit Care       Date:  2002-08-21       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.